MEAGAN MCFARLAND: Open Payments
NPI 1609155548 · SALEM, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$989 in 39 payments from 20 companies in 2025. Trend: 2023 $96 · 2024 $1,338 · 2025 $989
Food & beverage: $989
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 6 | $243 |
| AstraZeneca Pharmaceuticals LP | 4 | $85 |
| Merck Sharp & Dohme LLC | 3 | $68 |
| PFIZER INC. | 3 | $62 |
| Exelixis Inc. | 2 | $57 |
| GENZYME CORPORATION | 2 | $50 |
| ABBVIE INC. | 2 | $46 |
| E.R. Squibb & Sons, L.L.C. | 2 | $45 |
| TerSera Therapeutics LLC | 2 | $45 |
| Agios Pharmaceuticals, Inc. | 1 | $40 |
Products named: RYBREVANT, KEYTRUDA, TALVEY, CABOMETYX, SARCLISA, VENCLEXTA, IBRANCE, Xermelo.
Industry payments across OR — which companies pay providers there.
